InfuSystem Holdings, Inc.

As of October 31, 2025, InfuSystem Holdings, Inc. is considered very expensive and overvalued, with a P/E ratio of 47, an EV to EBITDA of 8.31, and a PEG ratio of 0.01, indicating high valuation compared to its peers.

As of October 31, 2025, InfuSystem Holdings, Inc. is considered very expensive with a P/E ratio of 47, overvalued compared to peers, despite strong recent performance, as its long-term returns significantly lag behind the S&P 500.

As of October 31, 2025, InfuSystem Holdings, Inc. is considered very expensive with a P/E ratio of 47, significantly overvalued compared to industry peers, despite a strong recent stock performance of 67.37% over the past year, while its long-term returns remain poor at -15.91% over five years.

As of October 17, 2025, InfuSystem Holdings, Inc. is considered very expensive with a high P/E ratio of 47, overvalued compared to peers, and despite a recent 28.57% return outperforming the S&P 500, its long-term performance raises concerns about sustainability at current valuation levels.

As of October 17, 2025, InfuSystem Holdings, Inc. is considered very expensive with a P/E ratio of 47, indicating overvaluation compared to peers and minimal growth expectations, despite its current price of $9.00.

As of October 17, 2025, InfuSystem Holdings, Inc. is considered very expensive and overvalued, with a P/E ratio of 47 and a year-to-date return of 6.51%, significantly underperforming the S&P 500's 13.30% return.

As of September 26, 2025, InfuSystem Holdings, Inc. is considered very expensive and overvalued due to its high P/E ratio of 47 and other valuation metrics, despite a strong one-year stock return of 57.62%, while long-term performance has declined by 25.18% over five and ten years.

As of September 9, 2025, InfuSystem Holdings, Inc. has a bullish technical trend with strong daily moving averages and positive MACD and KST indicators, despite some bearish RSI readings, and has outperformed the S&P 500 year-to-date with an 18.82% return compared to 12.22%.

As of September 5, 2025, InfuSystem Holdings, Inc. is considered very expensive and overvalued with a P/E ratio of 47, an EV to EBITDA ratio of 8.31, and a PEG ratio of 0.01, despite a strong 1-year return of 59.37% compared to the S&P 500's 17.14%, although its 3-year return of 39.06% lags behind the S&P's 70.41%.

As of June 12, 2025, InfuSystem Holdings, Inc. is considered overvalued with a P/E ratio of 47, significantly higher than industry peers, and has underperformed the S&P 500, declining 26.86% year-to-date.

As of May 29, 2025, InfuSystem Holdings, Inc. shows a mildly bearish trend, with daily moving averages indicating bearishness, while weekly indicators present mixed signals, suggesting a lack of strong momentum overall.

As of March 2022, the management team of InfuSystem Holdings, Inc. includes Mr. Scott Shuda (Independent Chairman), Mr. Richard Diiorio (President and CEO), Dr. Gregg Lehman (Vice Chairman), and three Independent Directors: Mr. Paul Gendron, Mr. Darrell Montgomery, and Mr. Christopher Sansone. They oversee the company's strategic direction and governance.

InfuSystem Holdings, Inc. provides infusion pumps and related services for patients in various care settings, with a market cap of approximately $150.88 million. As of March 2025, it reported net sales of $35 million and no net profit.

As of Jun 18, InfuSystem Holdings, Inc. has a market capitalization of 150.88 million, with net sales of 137.59 million and a net profit of 3.19 million over the latest four quarters.